---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-025636"
form_type: "8-K"
ticker: "FOXO"
cik: "0001812360"
company_name: "FOXO TECHNOLOGIES INC."
filed_at: "2026-05-28T20:45:42+00:00"
generated_at: "2026-05-28T20:50:16.918616+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# FOXO licenses epigenetics IP to founder's entity; 3% royalty capped at $1.3M, 40% equity option

## Summary
- Exclusive worldwide license of two U.S. patents, 13,000+ dataset, and ML models to LongevityFP Technologies, controlled by founder Jon R. Sabes.
- Royalty of 3% of net revenues from commercialization, aggregate cap of $1.3 million.
- Ten-year option for LongevityFP to acquire majority (60% or 100%) of FOXO Labs; if exercised, FOXO gets 40% equity interest.
- Agreement includes mutual releases resolving all prior matters between FOXO and founder Jon Sabes.
- FOXO retains ownership of FOXO Labs and all licensed IP throughout the license period.

## SEC filing metadata
- accession: 0001493152-26-025636
- form_type: 8-K
- ticker: FOXO
- cik: 0001812360
- company_name: FOXO TECHNOLOGIES INC.
- filed_at: 2026-05-28T20:45:42+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1812360/000149315226025636/0001493152-26-025636-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1812360/000149315226025636/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-025636
- JSON: https://secwatch.observer/filing/0001493152-26-025636.json
- Plain text: https://secwatch.observer/filing/0001493152-26-025636.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.